City Therapeutics

City Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered at 399 Binney Street in Kendall Square, Cambridge, Massachusetts, founded in 2024 by pioneers of RNA interference including John Maraganore, Phillip Zamore, Kotaro Nakanishi, Yukihide Tomari and Mark Keating. The company engineers next-generation RNAi trigger molecules — including its proprietary cleavage-inducing tiny (city) RNAs — and pairs them with precision targeting ligands designed to deliver siRNAs beyond the liver into ocular, CNS and other extrahepatic tissues. Its pipeline includes CITY-FXI, a Factor XI-targeting candidate for thromboembolic disease, and CITY-RBP4 for Stargardt disease and geographic atrophy, alongside undisclosed hepatic, ocular and CNS programs. City Therapeutics raised a $135M Series A in October 2024 and a $99.5M Series B in June 2026, and holds research collaborations with Biogen and Bausch + Lomb. City Therapeutics publishes no public developer program, API, or machine-readable interface; it is catalogued here as a company profile only.

City Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Therapeutics.

City Therapeutics’ developer surface includes product news, engineering blog, and 13 more developer resources.

🌐 Visit website 📡 Source on GitHub

12.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesTherapeuticsRNAiDrug DiscoveryClinical StageGenetic Medicine

Kin Score

Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1

Composite quality — 12.4/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.9 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/city-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 7

The organization behind the API

Website

About

News

Blog

BlogRSS

Careers

LinkedIn

Scroll for all 7

Other 3

Properties that don't map to a standard resource type

Pipelines

Pipelines

Team

Team

Source (apis.yml)

aid: city-therapeutics
name: City Therapeutics
description: City Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered at 399 Binney
  Street in Kendall Square, Cambridge, Massachusetts, founded in 2024 by pioneers of RNA interference including John Maraganore,
  Phillip Zamore, Kotaro Nakanishi, Yukihide Tomari and Mark Keating. The company engineers next-generation RNAi trigger molecules
  — including its proprietary cleavage-inducing tiny (city) RNAs — and pairs them with precision targeting ligands designed
  to deliver siRNAs beyond the liver into ocular, CNS and other extrahepatic tissues. Its pipeline includes CITY-FXI, a Factor
  XI-targeting candidate for thromboembolic disease, and CITY-RBP4 for Stargardt disease and geographic atrophy, alongside
  undisclosed hepatic, ocular and CNS programs. City Therapeutics raised a $135M Series A in October 2024 and a $99.5M Series
  B in June 2026, and holds research collaborations with Biogen and Bausch + Lomb. City Therapeutics publishes no public developer
  program, API, or machine-readable interface; it is catalogued here as a company profile only.
url: https://raw.githubusercontent.com/api-evangelist/city-therapeutics/refs/heads/main/apis.yml
image: https://static1.squarespace.com/static/65394e1483a04e2c2e68081e/t/690d09920cff71704ef4c257/1762462098341/City-Website-Logo-110625.png?format=1500w
x-type: company
x-source: harvest:secondary-market
x-source-url: https://forgeglobal.com/city-therapeutics_stock/
x-tier: profile
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Therapeutics
- RNAi
- Drug Discovery
- Clinical Stage
- Genetic Medicine
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/city-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/city-therapeutics-llms.txt
- type: Website
  url: https://www.citytx.com/
- type: About
  url: https://www.citytx.com/home#Approach
- type: Pipelines
  url: https://www.citytx.com/home#pipeline
- type: Team
  url: https://www.citytx.com/home#team
- type: News
  url: https://www.citytx.com/news
- type: Blog
  url: https://www.citytx.com/news
- type: BlogRSS
  url: https://www.citytx.com/news?format=rss
- type: Careers
  url: https://boards.greenhouse.io/citytherapeutics
- type: Contact
  url: https://www.citytx.com/home#contact
- type: TermsOfService
  url: https://www.citytx.com/terms-of-use
- type: PrivacyPolicy
  url: https://www.citytx.com/privacy-policy
- type: LinkedIn
  url: https://www.linkedin.com/company/city-therapeutics/
- type: X
  url: https://x.com/CityTx_
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 3
  pass: local-v1